Literature DB >> 7485190

Asbestos-induced visceral pleural fibrosis reduces pulmonary compliance.

E H Valkila1, M M Nieminen, A K Moilanen, P A Kuusisto, A H Lahdensuo, J I Karvonen.   

Abstract

To determine the nature of respiratory functional impairment caused by asbestos-induced visceral pleural fibrosis (VPF) and to discover which pulmonary physiological variable best reveals it, we examined 59 asbestos-exposed construction workers having asbestos-related changes on chest radiographs. Computed tomography scans of the thorax were also performed. Visceral pleural fibrosis was diagnosed in 29 subjects: seven had only VPF, 17 had VPF and pleural plaques, and five had VPF, plaques, and asbestosis. In subjects without VPF, 23 had plaques, six had plaques and asbestosis, and one had only minor fibrotic parenchymal changes insufficient for a diagnosis of asbestosis. Flow-volume spirometry, body plethysmography, static and dynamic compliance, and pulmonary diffusing capacity for carbon monoxide were measured. The subjects with VPF had significantly lower static (p = 0.005) and dynamic (p = 0.007) compliance values than those without. Other respiratory function variables failed to show any significant differences. We conclude that the measurement of static and dynamic compliance is a useful method in assessing pulmonary function impairment caused by visceral pleural fibrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485190     DOI: 10.1002/ajim.4700280306

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  2 in total

1.  The validity of static lung compliance in asbestos-induced diseases.

Authors:  Joachim Schneider; Rolf Arhelger; Wolfgang Raab; Kurt Georg Hering
Journal:  Lung       Date:  2012-04-20       Impact factor: 2.584

Review 2.  Systematic review of pleural plaques and lung function.

Authors:  Laura E Kerper; Heather N Lynch; Ke Zu; Ge Tao; Mark J Utell; Julie E Goodman
Journal:  Inhal Toxicol       Date:  2014-12-18       Impact factor: 2.724

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.